REHOVOT, Israel and BETHESDA, MD , Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder Prof. Benjamin Dekel (MD, PhD) will continue to serve as the company's Chief Scientist; CNBX... Read More

CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company has filed a new patent application titled " COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER" under the Patent Cooperation Treaty (PCT). Said patent application relates to several of the drug candidates currently under development... Read More

CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company's patent application titled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application. National... Read More

CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the peer-reviewed publication of its sponsored preclinical study titled " The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue" in the International Journal of Molecular... Read More

CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has received Notice of Grant for Patent by IP Australia, the Australian Government. Said notice relates to Company's patent titled: System and Method for High Throughput Screening of Cancer Cells . The term of the patent granted is set for 20 years starting May 2016 and until May... Read More

CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, today announced that it has received a Grant of Patent notice by the Patent Registry, Intellectual Property Department, The Government of the Hong Kong Special Administrative Region. Said notice relates to the Company's patent titled: System and Method for High Throughput Screening of Cancer Cells . The... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has changed its corporate name to "CNBX Pharmaceuticals Inc." The Company's new brand identity reflects the significant transformation that has already taken place across the Company's platform, as well as the team's forward-looking approach to molecule-based drug development... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has signed an agreement with Purisys, a leading Active Pharmaceutical Iingredient (API) manufacturer, for supply of Good Manufacturing Practice (GMP) grade APIs required for the manufacturing of RCC-33, the company's colorectal cancer treatment drug candidate. Under said... Read More

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company Scientific Advisory Board Member, Dr. Yonina Tova (MD), an internationally recognized Radiation Oncologist, will be attending the American Society of Radiologic Technologists (ASRT) Radiation Therapy Conference (RTC) in Chicago on October 26, 2021 . Company Director and... Read More

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Dr. Yonina Tova (MD), internationally recognized Radiation Oncologist has joined the company's Board of Advisors. Dr. Tova obtained her Medical Degree from the College of Medicine, University of Illinoi, Chicago , in 1986. Dr. Tova specializes in treating cancer with radiation,... Read More

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that EDISON Group issued a Healthcare QuickView publication on the company prepared by Analyst Will Manuel . The publication details Company's plans for Phase I/II(a) clinical studies for its colorectal cancer treatment drug candidate RCC-33, as well as other recent updates on company's... Read More

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company Director, Dr. Inbar Maymon-Pomeranchik, will participate at the MjBizCon in Las Vegas on 20-22 of October, 2021. Dr. Maymon-Pomeranchik will be present at the Regulatory Panel Session and will be available for one-on-one meetings after the session to further discuss our... Read More

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad , will present at the upcoming Edison Open Forum: Cannabinoids 2021 , taking place today, Wednesday, October 19 th . Mr. Barad's talk will focus on the... Read More

Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer... Read More

Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that CEO Eyal Barad and Dr. David Sans FAARM, PhD, MBA in New York , will participate at the upcoming Benzinga's Cannabis Capital Conference in NYC on 14-15 of October. Parties interested in contacting Cannabics Pharmaceuticals, CNBX, should contact CEO Eyal Barad at eyalbarad@cannabics.com... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website. In addition, the company announced that a... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4 th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston . Our team will be participating along with others from across the... Read More

Cannabics Pharmaceuticals Inc . (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases. This announcement comes following the company's commitment to expand the current drug development programs with second generation of synthetic... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine. The nomination of Dr. Reznik is part of the company's strategy to develop new psychedelic... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Dr. Sigal Tavor (MD), a renowned Hemato-Oncology expert, has joined the company's Board of Advisors. The announcement follows the company's recent expansion of its Board of... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Prof. Caroline Robert (MD. Ph.D.), a world-renowned expert on Melanoma has joined the company's Board of Advisors. The announcement follows the company's decision to initiate research aimed at the development of a new Melanoma treatment based on the company's unique expertise and... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the company's Board, is a world-renowned economist and currently serves also as the company's Head of Advisory Board. Dr. Feiler... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director. Dr. Maymon-Pomeranchik, 43, is trained as a molecular and genetic researcher holding a PhD from the Hebrew University , and brings nearly 20 years of executive level experience in... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the interim results of its second in-vivo POC study evaluating the efficacy of company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice. The study objective was to evaluate the potential efficacy of the RCC-33 drug candidate as a systemic treatment for... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases. The announcement of the new research projects follows promising initial preclinical results obtained in the company's in-house drug discovery... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Breast Cancer antitumor targeting medicine. The announcement comes following the launching of a Melanoma research... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company's patent titled: "System and Method for High Throughput Screening of Cancer Cells" has been granted by the European Patent Office . Outside the European territory, corresponding patents under the same title have already been granted in Israel and in South Africa.... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had filed a patent application under the Patent Cooperation Treaty (PCT) for novel formulations developed for treatment of various cancer types. Said patent application includes ample preclinical supporting data collected from in-vitro experiments performed in the company's... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had received "Notice of Allowance" from the Mexican Patent and Trademark Office (IMPI) in relation to the company's patent titled: 'System and method for high throughput... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Melanoma antitumor targeting medicine. The announcement comes amidst the recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin and Psilocin. The announcement comes after the company was able to obtain a license from the Israeli Ministry of Health to conduct scientific research using Psylocibin and Psilocin in the company's in-house laboratory facilities... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration along with a Pre-IND meeting request. The Dose Response Study comes in light of previously reported results indicating... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021 , that said study results showing "a significant and robust inhibitory effect on tumor growth, as evidenced by a... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice. The final study... Read More

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cancer in nude-mice. The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham... Read More